Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
AIMS: Proprotein convertase subtilisin kexin 9 (PCSK9) is an emerging target for the treatment of hypercholesterolaemia, but the clinical utility of PCSK9 levels to guide treatment is unknown. We aimed to prospectively assess the prognostic value of plasma PCSK9 levels in patients with acute coronary syndromes (ACS). METHODS AND RESULTS: Plasma PCSK9 levels were measured in 2030 ACS patients undergoing coronary angiography in a Swiss prospective cohort. At 1 year, the association between PCSK9 tertiles and all-cause death was assessed adjusting for the Global Registry of Acute Coronary Events (GRACE) variables, as well as the achievement of LDL cholesterol targets of <1.8 mmol/L. Patients with higher PCSK9 levels at angiography were more likely to have clinical familial hypercholesterolaemia (rate ratio, RR 1.21, 95% confidence interval, CI 1.09-1.53), be treated with lipid-lowering therapy (RR 1.46, 95% CI 1.30-1.63), present with longer time interval of chest pain (RR 1.29, 95% CI 1.09-1.53) and higher C-reactive protein levels (RR 1.22, 95% CI 1.16-1.30). PCSK9 increased 12-24 h after ACS (374 ± 149 vs. 323 ± 134 ng/mL, P < 0.001). At 1 year follow-up, HRs for upper vs. lower PCSK9-level tertiles were 1.13 (95% CI 0.69-1.85) for all-cause death and remained similar after adjustment for the GRACE score. Patients with higher PCSK9 levels were less likely to reach the recommended LDL cholesterol targets (RR 0.81, 95% CI 0.66-0.99). CONCLUSION: In ACS patients, high initial PCSK9 plasma levels were associated with inflammation in the acute phase and hypercholesterolaemia, but did not predict mortality at 1 year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 1×
“To analyse the incremental value of adding continuous PCSK9 variable to the recommended GRACE score mortality risk prediction model, we calculated C-index and integrated discrimination improvement (IDI).(22) Two GRACE scores were calculated for each patient: (1) in-hospital GRACE score(23) used for the 30 days outcome…”
MethodESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Third Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., & White, H. D. (2012) · Circulation · doi:10.1161/cir.0b013e31826e1058 · Cited by 2,985
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“inhibitor trials demonstrated up to 50% reduction in major adverse cardiovascular (CV) events in high-risk patients after acute coronary syndromes (ACS) or familial hypercholesterolaemia.(7,8) We have shown clinical familial hypercholesterolaemia to be highly prevalent among patients with ACS (20%), and LDL cholestero…”
BackgroundEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Nuesch, E., Dieppe, P., Reichenbach, S., Williams, S., Iff, S., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.d1165 · Cited by 730 · cited 2×
“**Continuous variables were divided by 2 standard deviation as done in a previous publication(19) and presented using forest plots.(20) hs-CRP, highsensitive C-reactive protein; PCSK9, proprotein convertase subtilisin kexin 9.”
MethodSeidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596 · cited 2×
“Proprotein convertase subtilisin kexin 9 reduced the uptake of LDL cholesterol by increasing the endosomal and lysosomal degradation of LDL receptor, yielding an increase of circulating LDL.(3) Observational studies have shown that loss-of-function mutations of PCSK9 were associated with low levels of LDL cholesterol…”
BackgroundBerge, K. E., Ose, L., & Leren, T. P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204337.81286.1c · Cited by 236 · cited 1×
“If experimental studies among humans showed that the use of statins is associated with an elevation in PCSK9 levels,(12,27,28) the impact of PCSK9 levels on the effects of statin therapy has been poorly described.(29) In the present study, we observed that higher levels of PCSK9 levels at coronary angiography were ass…”
Stairs instead of elevators at the workplace decreases PCSK 9 levels in a healthy population
Kamani, C. H., Gencer, B., Montecucco, F., Courvoisier, D., Vuilleumier, N., Meyer, P., & Mach, F. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12480 · Cited by 46 · cited 2×
“We have previously shown that PCSK9 levels were correlated to physical activity in healthy volunteers, and could be used as a marker of preventive interventions.(30) However, it is a source of controversy whether PCSK9 can give additional information beyond current available risk stratification post-ACS to become an i…”
BackgroundResultSelf-citation
Cited by
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Tang, Z.-H., Peng, J., Ren, Z., Yang, J., Li, T.-T., Li, T.-H., Wang, Z., Wei, D.-H., Liu, L.-S., Zheng, X.-L., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.023 · Cited by 291
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
PCSK9 and inflammation: a review of experimental and clinical evidence
Momtazi-Borojeni, A. A., Sabouri-Rad, S., Gotto, A. M., Pirro, M., Banach, M., Awan, Z., Barreto, G. E., & Sahebkar, A. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz022 · Cited by 188
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Macchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01158-6 · Cited by 51
Metadata
- Authors
- Gencer, B., Montecucco, F., Nanchen, D., Carbone, F., Klingenberg, R., Vuilleumier, N., Aghlmandi, S., Heg, D., Räber, L., Auer, R., Jüni, P., Windecker, S., Lüscher, T. F., Matter, C. M., Rodondi, N., & Mach, F.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12-09
- Volume
- 37
- Issue
- 6
- Pages
- 546-553
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2194053990
- Cited by
- 158
- References
- 10
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic value of PCSK9 levels in patients with acute coronary syndromes. https://app.cochat.ai/papers/10.1093/eurheartj/ehv637
- The paper
- Gencer, B., Montecucco, F., Nanchen, D., Carbone, F., Klingenberg, R., Vuilleumier, N., Aghlmandi, S., Heg, D., Räber, L., Auer, R., Jüni, P., Windecker, S., Lüscher, T. F., Matter, C. M., Rodondi, N., & Mach, F. (2016). Prognostic value of PCSK9 levels in patients with acute coronary syndromes. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv637
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.